Extraction form for project: Management of Infantile Epilepsies

Design Details

1. Study Design
2. Country
3. Total sample size
4. Intervention Type
5. Funding source

Arms

Arm NameArm Description
Topiramate 3 mg/kg/d3 mg/kg/d
Topiramate 5 mg/kg/d5 mg/kg/d
Topiramate 15 mg/kg/d15 mg/kg/d
Topiramate 25 mg/kg/d25 mg/kg/d

Arm Details

1. Sample size for arm
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
2. Inclusion Criteria
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
3. Exclusion Criteria
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
4. Treatment details
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d

Sample Characteristics

1. Gender, number of male
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
2. Gender, percentage of male
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
3. Age at intervention (mean)
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
4. Age at intervention (SD)
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
5. Age at intervention (range)
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
6. Age at intervention (median)
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
7. Seizure types and/or etiology
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
8. Prior treatment
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total
9. Comments
Topiramate 3 mg/kg/d
Topiramate 5 mg/kg/d
Topiramate 15 mg/kg/d
Topiramate 25 mg/kg/d
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalAdverse EventAnorexia
  • All Participants
  • 13.4 months
CategoricalAdverse EventBronchitis
  • All Participants
  • 13.4 months
CategoricalAdverse EventCoughing
  • All Participants
  • 13.4 months
CategoricalAdverse EventDiarrhea
  • All Participants
  • 13.4 months
CategoricalAdverse EventFever
  • All Participants
  • 13.4 months
CategoricalAdverse EventNephrolithiasis
  • All Participants
  • 13.4 months
CategoricalAdverse EventOtitis media
  • All Participants
  • 13.4 months
CategoricalAdverse EventRhinitis
  • All Participants
  • 13.4 months
CategoricalAdverse EventSomnolence
  • All Participants
  • 13.4 months
CategoricalAdverse EventUpper resp tract inf
  • All Participants
  • 13.4 months
CategoricalAdverse EventViral infection
  • All Participants
  • 13.4 months
CategoricalAdverse EventVomiting
  • All Participants
  • 13.4 months
CategoricalAdverse EventWeight decrease
  • All Participants
  • 13.4 months
CategoricalAdverse EventWithdrawal due to AE
  • All Participants
  • 13.4 months
CategoricalAdverse EventTreatment-emergent serious adverse event
  • All Participants
  • 13.4 months

Outcome Details

1. For RCTs: Generation of randomization sequence
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
2. For RCTs: Allocation concealment
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
3. For RCTs: Baseline imbalance
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
4. For RCTs: Patient blinded
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
5. For RCTs: Staff blinded
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
6. For RCTs: Differential ancillary treatments
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
7. For RCTs: Adherence
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
8. For RCTs: Analytic approach to address departures from intended intervention
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
9. For RCTs: Data on at least 80% of those enrolled
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
10. For RCTs: Differential dropout <=15%
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
11. For RCTs: Standard way to measure the outcome
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
12. For RCTs: Blinded outcome assessor
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
13. For RCTs: Bias in selection of reported results
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
14. For nonrandomized comparative studies: Confounding
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
15. For nonrandomized comparative studies: Selection into study
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
16. For nonrandomized comparative studies: Classification of interventions
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
17. For nonrandomized comparative studies: Differential ancillary treatments
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
18. For nonrandomized comparative studies: Adherence
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
19. For nonrandomized comparative studies: Data on at least 80% of those enrolled
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
20. For nonrandomized comparative studies: Differential dropout <=15%
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
21. For nonrandomized comparative studies: Standard way to measure the outcome
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
22. For nonrandomized comparative studies: Blinded outcome assessor
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
23. For nonrandomized comparative studies: Bias in selection of reported result
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
24. For single arm studies: Does the design or analysis control account for important confounding and modifying variables through matching, stratification, multivariable analysis, or other approaches?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
25. For single arm studies: Did researchers rule out any impact from a concurrent intervention or an unintended exposure that might bias results?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
26. For single arm studies: Did the study maintain fidelity to the intervention protocol?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
27. For single arm studies: If attrition (overall or differential nonresponse, dropout, loss to follow-up, or exclusion of participants) was a concern, were missing data handled appropriately (e.g., intention-to-treat analysis and imputation)?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
28. For single arm studies: Were the outcome assessors blinded to the intervention or exposure status of participants?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
29. For single arm studies: Were interventions/exposures assessed/defined using valid and reliable measures, implemented consistently across all study participants?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
30. For single arm studies: Were outcomes assessed/defined using valid and reliable measures, implemented consistently across all study participants?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
31. For single arm studies: Were confounding variables assessed using valid and reliable measures, implemented consistently across all study participants?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
32. For single arm studies: Were the potential outcomes prespecified by the researchers? Are all prespecified outcomes reported?
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event
Adverse Event

Risk of Bias Assessment

1. For Risk of Bias Assessment results, see Outcome Details section.

Results

Categorical


Adverse Event (Anorexia)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Bronchitis)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Coughing)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Diarrhea)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Fever)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Nephrolithiasis)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Otitis media)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Rhinitis)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Somnolence)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Upper resp tract inf)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Viral infection)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Vomiting)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Weight decrease)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Withdrawal due to AE)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d

Adverse Event (Treatment-emergent serious adverse event)

All Participants
Descriptive StatisticsBetween Arm Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d
13.4 months
Total (N analyzed)
Odds Ratio (OR)
Events
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
Topiramate 3 mg/kg/dTopiramate 5 mg/kg/dTopiramate 15 mg/kg/dTopiramate 25 mg/kg/d